news
Serina Therapeutics starts dosing trial for Parkinson's drug
Serina Therapeutics just completed dosing the first cohort of 8 patients in its Phase 1b trial for SER-252, a new treatment for advanced Parkinson's disease. This moves quicker than expected, with the US and Australian trial sites finishing before the 2026 guidance. It matters because SER-252 uses a novel polymer to deliver a dopamine-boosting drug via continuous subcutaneous infusion, aiming to smooth out those tricky dopamine level fluctuations that make life so tough for Parkinson's patients.
Serina Therapeutics just completed dosing the first cohort of 8 patients in its Phase 1b trial for SER-252, a new treatment for advanced Parkinson's disease. This moves quicker than expected, with the US and Australian trial sites finishing before the 2026 guidance. It matters because SER-252 uses a novel polymer to deliver a dopamine-boosting drug via continuous subcutaneous infusion, aiming to smooth out those tricky dopamine level fluctuations that make life so tough for Parkinson's patients.
The architecture take
Okay, so Serina Therapeutics is moving fast on their new Parkinson's drug. The goal here is steady dopamine support rather than fluctuating doses. Parkinson's is all about wonky dopamine neurons, and existing treatments often create a rollercoaster of 'on' and 'off' periods. A continuous, controlled release, like this polymer-based SER-252 promises, could mean a lot less of that neurochemical chaos. Think fewer unpredictable shifts in motor control and a more stable nervous system overall. If this Phase 1b trial (and later ones) pans out, it's not just another treatment option; it's a fundamental shift in how we manage a progressive neurodegenerative disease. We'll be watching how this impacts daily function and the quality of life for folks grappling with dopamine dysregulation.